Achiral Endohedral Functionality Provides Stereochemical Control in Fe(II)-Based Self-Assemblies

Michael C. Young, Amber M. Johnson, Ana S. Gamboa and Richard J. Hooley.* Department of Chemistry, University of California, Riverside, CA 92521. richard.hooley@ucr.edu

Electronic Supplementary Information

1. General Information

¹H and ¹³C spectra were recorded on a Varian Inova 400 MHz or Varian Inova 500 MHz NMR spectrometer. DOSY spectra were recorded on a Bruker Avance 600 MHz spectrometer. Proton (¹H) chemical shifts are reported in parts per million (δ) with respect to tetramethylsilane (TMS, δ =0), and referenced internally with respect to the protio solvent impurity. Deuterated NMR solvents were obtained from Cambridge Isotope Laboratories, Inc., Andover, MA, and used without further purification. Mass spectra were recorded on an Agilent 6210 LC TOF mass spectrometer using electrospray ionization with fragmentation voltage set at 115 v and processed with an Agilent MassHunter Operating System. All other materials were obtained from Aldrich Chemical Company, St. Louis, MO, or TCI, Tokyo, Japan and were used as received. Solvents were dried through a commercial solvent purification system (Pure Process Technologies, Inc.). Molecular modeling (semi-empirical calculations) was performed using the AM1 force field using SPARTAN.¹

2. Synthesis of Compounds



4,4'-Methylene-bis[N-(2-pyridinylmethylene)benzenamine (7):

4,4'-diaminodiphenylmethane (512 mg, 2.58 mmol) and 2-pyridinecarboxaldehyde (500 μ L, 5.27 mmol) were combined in a 50 mL Erlenmeyer flask with stir bar. MeOH (25 mL) was added, followed by stirring for 24 h, after which point a precipitate was filtered. The crude

product was rinsed with hexanes (25 mL) and dried to give a cream solid (712 mg, 73%). ¹H NMR (400 MHz; CDCl₃) δ 8.73 (dq, *J* = 4.8, 0.8 Hz, 2H), 8.65 (s, 2H), 8.22 (d, *J* = 7.8 Hz, 2H), 7.82 (td, *J* = 7.8, 1.1 Hz, 2H), 7.38 (ddd, *J* = 7.8, 4.8, 1.1 Hz, 2H), 7.29 (s, 8H), 4.07 (s, 2H). ¹³C NMR (100 MHz; CDCl₃) δ 160.1, 154.8, 149.8, 149.1, 139.9, 136.8, 129.9, 125.1, 122.0, 121.5, 41.2. HRMS (ESI) m/z calcd for C₂₅H₂₀N₄ ([M+H]⁺) 377.1760, found 377.1719.



1,3-Bis[(4-aminophenyl)ethynyl]benzene (A):

m-Diiodobenzene (500 mg, 1.52 mmol) was combined with 4-ethynylaniline (443 mg, 3.78 mmol), [1,1'-Bis-(diphenylphosphino)ferrocene] dichloropalladium(II) complexed with CH₂Cl₂ (62 mg, 76 µmol), and copper iodide (14 mg, 74 µmol) in a 25 mL round-bottomed flask with attached reflux condenser. The system was purged using a Schlenk line. Anhydrous iPr₂NH (2 mL) and anhydrous PhMe (8 mL) were added, followed by three additional purge cycles. The reaction was then heated to 100°C for 48 h. After cooling, the reaction was diluted with Et₂O (250 mL) and filtered through celite. The solvent was then evaporated *in vacuo*. The residue from this was purified by column chromatography (SiO₂; hexanes/ethyl acetate 3:1 + 1% Et₃N to hexanes/ethyl acetate 1:1 + 1% Et₃N). Collection of fractions and evaporation of solvent *in vacuo* gave product as a dull yellow solid (132 mg, 28%). ¹H NMR (400 MHz; CDCl₃) δ 7.63 (s, 1H), 7.39 (dd, *J* = 7.5, 1.1 Hz, 2H), 7.33 (d, *J* = 8.6 Hz, 4H), 7.28 (d, *J* = 7.5 Hz, 1H), 6.64 (d, *J* = 8.6 Hz, 4H), 3.82 (br, 4H). ¹³C NMR (100 MHz; CDCl₃) δ 146.9, 134.2, 133.2, 130.6, 128.4, 124.3, 114.9, 90.7, 86.9. HRMS (ESI) m/z calcd for C₂₂H₁₆N₂ ([M+H]⁺) 309.1386, found 309.1389.



2,6-Bis[(4-aminophenyl)ethynyl)]aniline (B):

2,6-Dibromoaniline (380 mg, 1.51 mmol), 4-ethynylaniline (443 mg, 3.78 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (62 mg,

76 μmol), and copper iodide (14 mg, 74 μmol) were combined in a 25 mL round-bottomed flask with attached reflux condenser. The system was purged using a Schlenk line. Anhydrous iPr₂NH (2 mL) and anhydrous PhMe (8 mL) were added, followed by three additional purge cycles. The reaction was then heated to 100°C for 48 h. After cooling, the reaction was diluted with Et₂O (250 mL) and filtered through celite. The solvent was then evaporated *in vacuo*. The residue from this was purified by column chromatography (SiO₂; hexanes/ethyl acetate 3:1 + 1% Et₃N to hexanes/ethyl acetate 1:1 + 1% Et₃N). Collection of fractions and evaporation of solvent *in vacuo* gave product as an orange solid (102 mg, 21%). ¹H NMR (400 MHz; CDCl₃) δ 7.33 (d, *J* = 8.4 Hz, 4H), 7.28 (d, *J* = 7.5 Hz, 2H), 6.65 (t, *J* = 7.5 Hz, 1H), 6.64 (d, *J* = 8.4 Hz, 4H), , 4.86 (br, 2H), 3.83 (br, 4H). ¹³C NMR (100 MHz; CDCl₃) δ 148.7, 146.8, 133.0, 131.8, 117.3, 114.9, 112.7, 108.2, 95.7, 83.5. HRMS (ESI) m/z calcd for C₂₂H₁₇N₃ ([M⁺]⁺) 323.1417, found 323.1427.



2,6-Bis[(**4-aminophenyl**)ethynyl]**4-nitroaniline** (**C**):

To a 2-neck 25 mL round-bottom flask equipped with a stir bar and reflux condenser was added 2,6-diiodo-4-nitroaniline (100 mg, 25 mmol), 4-ethynylaniline (58 mg, 50 mmol), bis(triphenylphosphino)dichloropalladium(II) (17.5 mg 2.5 mmol) and copper iodide (2.5 mg 1.3 mmol). The mixture was placed under nitrogen and anhydrous iPr₂NH (5 mL) was added. The reaction was stirred at room temperature for 40 h. The solvent was removed by rotary evaporation and the remaining solid was dissolved in a mixture of methylene chloride and methanol. The mixture was then filtered through celite and the solvent from the filtrate was removed by rotary evaporation. The product was recrystallized from methylene chloride twice to give an orange powder (32 mg, 33% yield). ¹H NMR (400 MHz; CDCl₃) δ 8.19 (s, 2H), 7.34 (d, J = 8.6 Hz, 4H), 6.66 (d, J = 8.6 Hz, 4H), 5.53 (br, 2H), 3.91 (br, 4H); ¹H NMR (400 MHz; DMSO-*d*₆) $\delta = 8.00$ (s, 2H), 7.34 (d, J = 8.6 Hz, 4H), 6.68 (br, 2H), 6.57 (d, J = 8.6 Hz, 4H), 5.64 (br, 4H). ¹³C NMR (100 MHz; DMSO-*d*₆) δ 153.4, 149.8, 136.1, 133.0, 126.5, 113.4, 107.5, 107.0, 98.0, 81.1. HRMS (ESI) m/z calcd for C₂₂H₁₆N₄O₂ ([M+H]⁺) 369.1346, found 369.1382.



Benzyl 2,6-Dibromophenyl Ether (S-1):

2,6-Dibromophenol (580 mg, 2.3 mmol), benzyl bromide (274 µL, 2.3 mmol), potassium carbonate (479 mg, 3.47 mmol), and sodium iodide (33 mg, 0.22 mmol) were combined in a 25 mL round-bottomed flask with attached reflux condenser. MeCN (7 mL) was added, and reaction was heated under reflux for 16 h. After cooling, water was added, followed by extraction with Et₂O. The combined organic fractions were washed with brine, dried over MgSO₄, followed by evaporation of solvent *in vacuo*. The crude product was then filtered through a silica plug with hexanes to yield a white solid (645 mg, 82%). ¹H NMR (400 MHz; CDCl₃) δ 7.61 (d, *J* = 7.2 Hz, 2H), 7.54 (d, *J* = 8.0 Hz, 2H), 7.44-7.35 (m, 3H), 6.90 (t, *J* = 8.0 Hz, 1H), 5.04 (s, 2H) . ¹³C NMR (100 MHz; CDCl₃) δ 153.0, 136.4, 132.9, 128.6, 128.5, 126.6, 118.9, 74.7 (two resonances are overlapping). HRMS (ESI) m/z calcd for C₁₃H₁₄Br₂NO ([M+NH₄]⁺) 359.9417, found 359.9432.



O-Benzyl 2,6-bis[(4-aminophenyl)ethynyl]phenol (D):

S-1 (250)0.73 mmol). 4-ethynylaniline (214)1.83 mg, mmol). mg, bis(triphenylphosphino)dichloropalladium(II) (60 mg, 0.09 mmol), and copper iodide (14 mg, 0.07 mmol) were combined in a 25 mL round-bottomed flask with attached reflux condenser. The system was purged using a Schlenk line. Anhydrous iPr₂NH (8 mL) and anhydrous THF (8 mL) were added, followed by three additional purge cycles. The reaction was then heated under reflux for 72 h. After cooling, the reaction was diluted with Et₂O (400 mL) and filtered through celite. The solvent was then evaporated in vacuo. The residue from this was triturated in 3 M aqueous KOH (20 mL) in an ultrasonication bath, followed by filtration and drying. The solid

was purified by column chromatography (SiO₂; hexanes/ethyl acetate 3:1 + 1% Et₃N to hexanes/ethyl acetate 1:1 + 1% Et₃N). Collection of fractions and evaporation of solvent *in vacuo* gave product as a light orange solid (32 mg, 10%). ¹H NMR (400 MHz; CDCl₃) δ 7.62 (d, J = 7.2 Hz, 2H), 7.42 (d, J = 7.7 Hz, 2H), 7.32 (m, 3H), 7.28 (d, J = 8.0 Hz, 4H), 7.04 (t, J = 7.7 Hz, 1H), 6.63 (d, J = 8.0 Hz, 4H), 5.34 (s, 2H), 3.83 (br, 4H). ¹³C NMR (100 MHz; CDCl₃) δ 160.1, 146.9, 137.7, 133.1, 132.7, 128.6, 128.5, 128.0, 123.8, 118.7, 114.9, 112.7, 94.9, 83.7, 75.6. HRMS (ESI) m/z calcd for C₂₉H₂₂N₂O ([M+Na]⁺) 437.1624, found 437.1646.



4-(t-Butyl)benzyl 2,6-Diiodo-4-nitrophenyl Ether (S-2):

2,6-Diiodo-4-nitrophenol (640 mg, 1.64 mmol), 4-(t-butyl) benzyl bromide (300 µL, 1.64 mmol), and potassium carbonate (283 mg, 2.05 mmol) were combined in a 25 mL round-bottomed flask with attached reflux condenser. MeCN (10 mL) was added, and reaction was heated under refluxed for 24 h. After cooling, water (100 mL) was added, followed by extraction with CH₂Cl₂ (3 x 50 mL). The combined organic fractions were dried over MgSO₄, followed by evaporation of solvent *in vacuo* to give a faint yellow solid (708 mg, 80%). ¹H NMR (400 MHz; CDCl₃) δ 8.69 (s, 2H), 7.60 (d, *J* = 8.3 Hz, 2H), 7.48 (d, *J* = 8.3 Hz, 2H), 5.06 (s, 2H), 1.37 (s, 9H). ¹³C NMR (100 MHz; CDCl₃) δ 162.9, 152.1, 144.8, 135.2, 132.2, 128.6, 125.7, 90.6, 75.0, 34.8, 31.5. HRMS (ESI) m/z calcd for C₁₇H₁₇I₂NO₃ ([M]⁺⁺) 536.9292, found 536.9290.



O-4-(t-Butyl)benzyl Bis[(4-aminophenyl)ethynyl]4-nitrophenol (E):

S-2 (638 2.97 1.19 mmol), 4-ethynylaniline (348)mg, mg, mmol), bis(triphenylphosphino)dichloropalladium(II) (42 mg, 0.06 µmol), and copper iodide (12 mg, 0.06 µmol) were combined in a 50 mL round-bottomed flask with attached reflux condenser. The system was purged using a Schlenk line. Anhydrous iPr₂NH (10 mL) and anhydrous PhMe (10 mL) were added, followed by three additional purge cycles. The reaction was then heated under reflux for 68 h. After cooling, the solvent was diluted with Et₂O (200 mL), followed by filtering through celite. The solvent was then removed in vacuo. The residue was dissolved in EtOAc (10 mL), followed by addition of hexanes (90 mL) to give a precipitate. The mixture was filtered through celite and rinsed with additional hexanes (100 mL), causing new precipitate to form. The fine solid was filtered through celite, rinsed with hexanes (50 mL), then washed off of the celite with EtOAc (50 mL). Solvent was removed in vacuo to give product as an orange solid (264 mg, 41%). ¹H NMR (400 MHz; CDCl₃) δ 8.23 (s, 2H), 7.52 (d, J = 8.2 Hz, 2H), 7.39 (d, J = 8.2 Hz, 2H), 7.29 (d, *J* = 8.4 Hz, 4H), 6.63 (d, *J* = 8.4 Hz, 4H), 5.48 (s, 2H), 3.71 (br, 2H), 1.33 (s, 9H). ¹³C NMR (100 MHz; CDCl₃) δ 164.5, 151.4, 147.5, 143.1, 133.8, 133.3, 128.3, 127.3, 125.5, 119.3, 114.8, 111.6, 97.3, 82.3, 75.7, 34.7, 31.5. HRMS (ESI) m/z calcd for C₃₃H₂₉N₃O₃ $([M+H]^+)$ 516.2281, found 516.2354.



1-(N-(2,6-Dibromophenyl))Adamantane Carboxamide (S-3):

2,6-Dibromoaniline (250 mg, 1.0 mmol) and 1-adamantanecarboxylic acid chloride (160 mg, 0.81 mmol) were combined in a 10 mL round-bottomed flask with attached reflux condenser. System was purged using a Schlenk line, followed by addition of anhydrous PhMe (5 mL). Reaction was heated under reflux for 28 h, followed by cooling and then evaporating the solvent *in vacuo*. The residue was then recrystallized from 95% EtOH to give the product as a white powder (103 mg, 31%). ¹H NMR (400 MHz; CDCl₃) δ 7.55 (d, *J* = 8.1 Hz, 2H), 7.21 (br, 1H), 6.99 (t, *J* = 8.1 Hz, 1H), 2.10 (s, 3H), 2.05 (s, 6H), 1.77 (s, 6H). ¹³C NMR (100 MHz; CDCl₃) δ 175.6, 135.1, 132.3, 129.3, 124.0, 41.6, 39.3, 36.6, 28.3. HRMS (ESI) m/z calcd for C₁₇H₁₉Br₂NO ([M+H]⁺) 411.9906, found 411.9913.



N-(2,6-bis[(4-aminophenyl)ethynyl]phenyl)adamantanecarboxamide (F):

S-3 (103)0.25 mmol), 4-ethynylaniline (73)0.62 mmol), mg, mg, bis(triphenylphosphino)dichloropalladium(II) (18 mg, 0.03 µmols), and copper iodide (5 mg, 0.03 µmols) were combined in a 25 mL round-bottomed flask with attached reflux condenser. The system was purged using a Schlenk line. Anhydrous iPr₂NH (5 mL) and anhydrous PhMe (10 mL) were added, followed by three additional purge cycles. The reaction was then heated under reflux for 72 h. After cooling, the reaction was filtered through celite, followed by removal of solvent in vacuo. The residue was then purified by column chromatography (SiO₂; hexanes/ethyl acetate 2:1 + 1% Et₃N to hexanes/ethyl acetate 1:1 + 1% Et₃N) to give the product as a light orange solid (17 mg, 14%). ¹H NMR (400 MHz; CDCl₃) δ 7.56 (br, 1H), 7.45 (d, J = Hz, 2H), 7.30 (d, J = Hz, 4H), 7.15 (t, J = Hz, 1H), 6.62 (d, J = Hz, 4H), 3.87 (br, 4H), 2.07 (s,

9H), 1.75 (s, 6 H). ¹³C NMR (100 MHz; CDCl₃) δ 175.5, 146.9, 138.8, 133.1, 131.8, 125.9, 121.5, 114.9, 112.6, 95.5, 84.3, 41.6, 39.7, 36.7, 28.4. HRMS (ESI) m/z calcd for C₃₃H₃₁N₃O ([M+H]⁺) 486.2539, found 486.2609.

Complex Formation

73.Fe2.(ClO4)4 (Method A):

7 (25.0 mg, 66.0 μ mol) and Fe(ClO₄)₂•xH₂O (17.2 mg) were combined in anhydrous MeCN (10 mL) in a 25 mL round-bottomed flask under a blanket of N₂, followed by submerging in an ultrasonication bath for two minutes. The solution was then diluted with Et₂O (200 mL), followed by filtration of the resulting precipitate. After drying, product was isolated as a purple solid (35.5 mg, 98%).

7₃·Fe₂·(ClO₄)₄ (Method B):

4,4'-Diaminodiphenylmethane (66 mg, 330 µmol) and 2-pyridinecarboxaldehyde (59 µL, 670 µmol) were combined in anhydrous MeCN (2 mL) in a 10 mL round-bottomed flask under a blanket of N₂. To this solution was added Fe(ClO₄)₂•xH₂O (122 mg). The mixture was then submerged in an ultrasonication bath for two minutes. The solution was then diluted with Et₂O (14 mL), and cooled to -25°C. This gave a fine precipitate which was collected by centrifugation to give a purple solid (183 mg, 82%). ¹H NMR (400 MHz; CD₃CN) δ 8.93 (s, 2H), 8.56 (d, *J* = 7.7 Hz, 2H), 8.37 (t, *J* = 7.7 Hz, 2H), 7.75 (t, *J* = 6.7 Hz, 2H), 7.35 (d, *J* = 5.2 Hz, 2H), 6.94 (br s, 4H), 5.52 (br s, 4H), 4.01 (s, 2H).

$1_3 \cdot Fe_2 \cdot (ClO_4)_4$:

A (3.9 mg, 13 µmol) and 2-pyridinecarboxaldehyde (2.5 µL, 26 µmol) were combined in anhydrous MeCN (1 mL) in a 10 mL round-bottomed flask under a blanket of N₂. To this solution was added Fe(ClO₄)₂•xH₂O (3.0 mg). The mixture was then submerged in an ultrasonication bath for two minutes. The solution was then diluted with Et₂O (14 mL), and cooled to -25°C. This gave a fine precipitate which was collected by centrifugation to give a purple solid (7.5 mg, 90%). ¹H NMR (500 MHz; CD₃CN) δ 8.93 (s, 2H), 8.54 (d, *J* = 7.5 Hz, 2H), 8.39 (t, *J* = 7.72 Hz, 2H), 7.85 (s, 1H), 7.79 (t, *J* = 6.0 Hz, 2H), 7.58 (d, *J* = 7.2 Hz, 2H),

7.45 (m, 7H), 5.33 (d, J = 8.2 Hz, 4H). HRMS (ESI) m/z calcd for $C_{102}H_{66}Cl_4Fe_2N_{12}O_{16}$ ([M+2H]²⁺) 984.1159, found 984.1167.

2₃•Fe₂•(ClO₄)₄:

B (8.5 mg, 26 µmol) and 2-pyridinecarboxaldehyde (5.5 µL, 58 µmol) were combined in anhydrous MeCN (1 mL) in a 10 mL round-bottomed flask under a blanket of N₂. To this solution was added Fe(ClO₄)₂•xH₂O (7.1 mg). The mixture was then submerged in an ultrasonication bath for two minutes. The solution was then diluted with Et₂O (14 mL), and cooled to -25°C. This gave a fine precipitate which was collected by centrifugation to give a purple solid (49.2 mg, 94%). ¹H NMR (400 MHz; CD₃CN) δ 8.89 (s, 2H), 8.52 (d, *J* = 7.6 Hz, 2H), 8.39 (t, *J* = 7.6 Hz, 2H), 7.77 (t, *J* = 6.1 Hz, 2H), 7.47 (d, *J* = 8.4 Hz, 4H), 7.38 (m, 4H), 6.71 (t, *J* = 7.6 Hz, 1H), 5.47 (br, 2H), 5.31 (d, *J* = 8.4 Hz, 4H). HRMS (ESI) m/z calcd for C₁₀₂H₆₉Cl₄Fe₂N₁₅O₁₆ ([M-3(ClO₄)]³⁺) 571.4676, found 571.4686.

33·Fe₂·(ClO₄)₄:

C (10.6 mg, 29 µmol) and 2-pyridinecarboxaldehyde (6.0 µL, 63 µmol) were combined in anhydrous MeCN (1 mL) in a 10 mL round-bottomed flask under a blanket of N₂. To this solution was added Fe(ClO₄)₂•xH₂O (7.0 mg). The mixture was then submerged in an ultrasonication bath for two minutes. The solution was then diluted with Et₂O (14 mL), and cooled to -25°C. This gave a fine precipitate which was collected by centrifugation to give a purple solid (15.6 mg, 76 %). ¹H NMR (500 MHz; CD₃CN) δ 8.87 (s, 2H), 8.53 (t, *J* = 8.2 Hz, 2H), 8.39 (t, *J* = 7.5 Hz, 2H), 8.24 (s, 2H), 7.77 (m, 2H), 7.57 (m, 4H), 7.39 (d, *J* = 8.1 Hz, 2H), 6.57 (br, 2H), 5.32 (d, *J* = 8.1 Hz, 4H). HRMS (ESI) m/z calcd for C₁₀₂H₆₆Cl₄Fe₂N₁₈O₂₂ ([M-3(ClO₄)]³⁺) 616.4526, found 616.4522.

43·Fe₂·(ClO₄)₄:

D (23.8 mg, 57 μ mol) and 2-pyridinecarboxaldehyde (11.0 μ L, 116 μ mol) were combined in anhydrous MeCN (1 mL) in a 10 mL round-bottomed flask under a blanket of N₂. To this solution was added Fe(ClO₄)₂•xH₂O (13.9 mg). The mixture was then submerged in an ultrasonication bath for two minutes. The solution was then diluted with Et₂O (14 mL), and cooled to -25°C. This gave a fine precipitate which was collected by centrifugation to give a

purple solid (35.8 mg, 82%). ¹H NMR (400 MHz; CD₃CN) δ 8.91 (s, 2H), 8.54 (d, *J* = 7.6 Hz, 2H), 8.39 (t, *J* = 8.0 Hz, 2H), 7.79 (t, *J* = 5.8 Hz, 2H), 7.59 (d, *J* = 7.6 Hz, 2H), 7.43 (m, 4H), 7.28 (d, *J* = 7.7 Hz, 4H), 7.22 (t, *J* = 7.7 Hz, 1H), 7.09 (t, *J* = 8.0 Hz, 2H), 6.83 (t, *J* = 7.7 Hz, 1H), 5.36 (d, *J* = 7.7 Hz, 4H), 5.19 (s, 2H). HRMS (ESI) m/z calcd for C₁₂₃H₈₄Cl₄Fe₂N₁₂O₁₉ ([M-2(ClO₄)]²⁺) 1043.2223, found 1043.2203.

5₃•Fe₂•(ClO₄)₄:

E (54.6 mg, 0.11 mmols) and 2-pyridinecarboxaldehyde (21 μL, 0.22 mmols) were combined in anhydrous MeCN (5 mL) in a 10 mL round-bottomed flask under a blanket of N₂. To this solution was added Fe(ClO₄)₂•xH₂O (26 mg). The mixture was then submerged in an ultrasonication bath for five minutes. The solution was then diluted with Et₂O (10 mL), and cooled to -25°C. This gave a fine precipitate which was collected by centrifugation to give a purple solid (41.4 mg, 45%). ¹H NMR (500 MHz; CD₃CN) δ 8.81 (s, 2H), 8.58 (d, *J* = 7.3 Hz, 2H), 8.42 (s, 2H), 8.40 (m, 2H), 7.77 (dd, *J* = 9.8 Hz, 3.7 Hz, 2H), 7.34 (d, *J* = 5.4 Hz, 2H), 7.29 (d, *J* = 8.2 Hz, 2H), 7.19 (d, *J* = 8.0 Hz, 4H), 7.13 (d, *J* = 8.2 Hz, 2H), 5.7 (s, 2H), 5.17 (d, *J* = 8.0 Hz, 4H), 1.09 (s, 9H). HRMS (ESI) m/z calcd for C₁₃₅H₁₀₅Cl₄Fe₂N₁₅O₂₅ ([M-4(ClO₄)]⁴⁺) 547.9224, found 547.9227.

3. NMR Spectral Data



Figure S-1. ¹H NMR spectrum of **7** (CDCl₃, 400 MHz, 298 K).



Figure S-2. ¹³C NMR spectrum of **7** (CDCl₃, 100 MHz, 298 K).



Figure S-3. ¹H NMR spectrum of A (CDCl₃, 400 MHz, 298 K).



Figure S-4. ¹³C NMR spectrum of A (CDCl₃, 100 MHz, 298 K).



Figure S-5. ¹H NMR spectrum of **B** (CDCl₃, 400 MHz, 298 K).



Figure S-6. ¹³C NMR spectrum of **B** (CDCl₃, 100 MHz, 298 K).



Figure S-7. ¹H NMR spectrum of C (CDCl₃, 400 MHz, 298 K).



Figure S-8. ¹³C NMR spectrum of C (CDCl₃, 100 MHz, 298 K).



Figure S-9. ¹H NMR spectrum of *S-1* (CDCl₃, 400 MHz, 298 K).



Figure S-10. ¹³C NMR spectrum of *S-1* (CDCl₃, 100 MHz, 298 K).



Figure S-11. ¹H NMR spectrum of **D** (CDCl₃, 400 MHz, 298 K).



Figure S-12. ¹³C NMR spectrum of **D** (CDCl₃, 100 MHz, 298 K).



Figure S-13. ¹H NMR spectrum of *S-2* (CDCl₃, 400 MHz, 298 K).





Figure S-15. ¹H NMR spectrum of **E** (CDCl₃, 400 MHz, 298 K).



Figure S-16. ¹³C NMR spectrum of **E** (CDCl₃, 100 MHz, 298 K).



Figure S-17. ¹H NMR spectrum of *S-3* (CDCl₃, 400 MHz, 298 K).



Figure S-18. ¹³C NMR spectrum of *S-3* (CDCl₃, 100 MHz, 298 K).



Figure S-19. ¹H NMR spectrum of \mathbf{F} (CDCl₃, 400 MHz, 298 K).



Figure S-20. ¹³C NMR spectrum of **F** (CDCl₃, 100 MHz, 298 K).



Figure S-21. ¹H NMR spectrum of **7₃·Fe₂·(ClO₄)**₄ (CD₃CN, 400 MHz, 298 K).



Figure S-22. ¹H NMR spectrum of **1**₃·Fe₂·(ClO₄)₄ (CD₃CN, 500 MHz, 298 K).



Figure S-23. ¹H NMR spectrum of 2₃·Fe₂·(ClO₄)₄ (CD₃CN, 400 MHz, 298 K).



Figure S-24. ¹H NMR spectrum of **3₃·Fe₂·(ClO₄)**₄ (CD₃CN, 400 MHz, 298 K).



Figure S-25. ¹H NMR spectrum of **4₃·Fe₂·(ClO₄)**₄ (CD₃CN, 600 MHz, 298 K).



Figure S-26. ¹H NMR spectrum of **5**₃·Fe₂·(ClO₄)₄ (CD₃CN, 400 MHz, 298 K).



Figure S-27. COSY NMR Spectrum of **4₃·Fe₂·(ClO₄)**₄ (CD₃CN, 500 MHz, 298 K).



Figure S-28. COSY NMR Spectrum of **5**₃·**F**e₂·(ClO₄)₄ (CD₃CN, 500 MHz, 298 K)



Figure S-29. 2D-ROESY NMR Spectrum of **4**₃•Fe₂•(ClO₄)₄ (CD₃CN, 600 MHz, 298 K)



Figure S-30. 2D-ROESY NMR Spectrum of **5**₃·Fe₂·(ClO₄)₄ (CD₃CN, 600 MHz, 298 K)



Figure S-31. Expanded 2D-ROESY NMR Spectrum of **5**₃•Fe₂•(ClO₄)₄ (CD₃CN, 600 MHz, 298 K)





Figure S-32. ESI-MS spectrum (MeCN) of 1₃·Fe₂·(ClO₄)₄.



Figure S-33. ESI-MS spectrum expansion (MeCN) of 1₃·Fe₂·(ClO₄)₄.



Figure S-34. ESI-MS spectra (MeCN) of $2_3 \cdot Fe_2 \cdot (ClO_4)_4$. Note $M^{3+} \sim 572$; singly charged complexes not observed, and other large peaks correspond to ligand.



Figure S-35. ESI-MS spectra expansion of $[2_3Fe_2 \cdot ClO_4]^{3+}$: a) Predicted, b) Observed.





Figure S-37. ESI-MS spectra blow-up of $[3_3Fe_2 \cdot ClO_4]^{3+}$: a) Predicted, b) Observed.



Figure S-38. ESI-MS spectra (MeCN) of 43. Fe2. (ClO₄)_{4.}



Figure S-39. ESI-MS spectra blow-up of $[4_3Fe_2 \cdot 2ClO_4]^{2+}$: a) Predicted, b) Observed.



Figure S-40. ESI-MS spectra blow-up of $[4_6Fe_4 \cdot 5ClO_4]^{3+}$: a) Predicted, b) Observed.



Figure S-41. ESI-MS spectra (MeCN) of 5₃·Fe₂·(ClO₄)₄.

Electronic Supplementary Material (ESI) for Chemical Communications This journal is The Royal Society of Chemistry 2013



Figure S-42. ESI-MS spectra blow-up of $[5_3Fe_2]^{4+}$: a) Predicted, b) Observed.



Figure S-43. ¹H-DOSY NMR spectrum of $1_3 \cdot Fe_2 \cdot (ClO_4)_4$ (CD₃CN, 600 MHz, 298 K, $\Delta = 17.0$ ms, $\delta = 7000 \ \mu$ s, Diffusion Coefficient = $5.46 \times 10^{-10} \ m^2/s \ vs. 3.85 \times 10^{-9} \ m^2/s$ for the solvent).



Figure S-44. ¹H-DOSY NMR spectrum of **2₃·Fe₂·(ClO₄)**₄ (CD₃CN, 600 MHz, 298 K, $\Delta = 17.0$ ms, $\delta = 7000$ μs, Diffusion Coefficient = 5.25×10^{-10} m²/s vs. 3.47×10^{-9} m²/s for the solvent).



Figure S-45. ¹H-DOSY NMR spectrum of $4_3 \cdot Fe_2 \cdot (ClO_4)_4$ (CD₃CN, 600 MHz, 298 K, $\Delta = 17.0$ ms, $\delta = 7000 \mu$ s, Diffusion Coefficient = 5.51×10^{-10} m²/s vs. 3.79×10^{-9} m²/s for the solvent).



Figure S-46. 1H-DOSY NMR spectrum of $5_3 \cdot Fe_2 \cdot (ClO4)_4$ (CD3CN, 600 MHz, 298 K, $\Delta = 17.0$ ms, $\delta = 7000 \ \mu$ s, Diffusion Coefficient = $4.20 \times 10^{-10} \ \text{m}^2/\text{s}$ vs. $3.79 \times 10^{-10} \ \text{m}^2/\text{s}$ for the solvent).

6. References

1) M. J. S. Dewar, E. G. Zoebisch, E. F. Healy, J. J. P. Stewart, *J. Am. Chem. Soc.*, **1985**, *107*, 3902-3909; calculations performed on SPARTAN 06, Wavefunction Inc.